RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Cytokinetics Equity 2024

Cytokinetics Equity

-386.32 M USD

Cytokinetics Dividend yield

Ticker

CYTK

ISIN

US23282W6057

WKN

A1W1KK

In 2024, Cytokinetics's equity was -386.32 M USD, a 258.04% increase from the -107.9 M USD equity in the previous year.

Cytokinetics Aktienanalyse

What does Cytokinetics do?

Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Cytokinetics's Equity

Cytokinetics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cytokinetics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cytokinetics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cytokinetics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cytokinetics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cytokinetics Stock

What is the equity of Cytokinetics this year?

Cytokinetics has equity of -386.32 M USD this year.

What was the equity of Cytokinetics compared to the previous year?

The equity of Cytokinetics has increased/decreased by 258.04% increased compared to the previous year.

What impact does a high equity have on investors of Cytokinetics?

A high equity is advantageous for investors of Cytokinetics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Cytokinetics?

A low equity can be a risk for investors of Cytokinetics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Cytokinetics affect the company?

An increase in equity of Cytokinetics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Cytokinetics affect the company?

A reduction in equity of Cytokinetics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Cytokinetics?

Some factors that can affect the equity of Cytokinetics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Cytokinetics so important for investors?

The equity of Cytokinetics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Cytokinetics take to change the equity?

To change equity, Cytokinetics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Cytokinetics pay?

Over the past 12 months, Cytokinetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cytokinetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cytokinetics?

The current dividend yield of Cytokinetics is .

When does Cytokinetics pay dividends?

Cytokinetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cytokinetics?

Cytokinetics paid dividends every year for the past 0 years.

What is the dividend of Cytokinetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cytokinetics located?

Cytokinetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cytokinetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cytokinetics from 5/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/18/2024.

When did Cytokinetics pay the last dividend?

The last dividend was paid out on 5/18/2024.

What was the dividend of Cytokinetics in the year 2023?

In the year 2023, Cytokinetics distributed 0 USD as dividends.

In which currency does Cytokinetics pay out the dividend?

The dividends of Cytokinetics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cytokinetics

Our stock analysis for Cytokinetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytokinetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.